Genocea Biosciences (NASDAQ:GNCA) Research Coverage Started at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report published on Saturday. The firm issued a sell rating on the biotechnology company's stock.
斯托克新闻网在周六发布的一份报告中对Genocea Biosciences(纳斯达克：GNCA-GET评级)的股票进行了报道。该公司对这家生物技术公司的股票发布了卖出评级。
Genocea Biosciences Price Performance
Genocea Bioscions价格表现
Shares of Genocea Biosciences stock opened at $0.01 on Friday. The firm has a market cap of $557,385.66, a price-to-earnings ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.16. The stock has a 50-day simple moving average of $0.01 and a 200-day simple moving average of $0.34.
Genocea Biosciences的股票上周五开盘报0.01美元。该公司市值为557,385.66美元，市盈率为-0.02，贝塔系数为1.96。该公司的债务权益比为0.24，流动比率为1.35，速动比率为1.35。Genocea Biosciences的52周低点为0.01美元，52周高位为2.16美元。该股的50日简单移动均线切入位为0.01美元，200日简单移动均线切入位为0.34美元。
Institutional Investors Weigh In On Genocea Biosciences
机构投资者参与Genocea Bioscions
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC bought a new position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 9.31% of the company's stock.
一家对冲基金最近购买了Genocea Biosciences股票的新股份。根据Acadian Asset Management LLC最近提交给美国证券交易委员会的13F文件，该公司在第四季度购买了Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET Rating)的一个新头寸。该基金购买了这家生物技术公司21,741股股票，价值约25,000美元。机构投资者和对冲基金持有该公司9.31%的股票。
About Genocea Biosciences
关于Genocea生物科学
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别，但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。